Melantonin Placebo

Phase 2

DDuke University

Melantonin Placebo is one of 6 therapeutic programs targeting Long COVID. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Long COVIDCompleted

Long COVIDPhase 2

Completed

Competition

Competitive Landscape

5 competitors in Long COVID

#DrugCompanyPhaseTrials

Circadin

NNeurim Pharmaceuticals Ltd.

Phase 2

1 2

Ketamine Only

UUniversity of Pennsylvania

Phase 2

1 3

Luvox

SSolvay Pharmaceuticals

Preclinical

1 4

Melantonin Placebo

DDuke University

Phase 2

1 5

Taurine

TThird Military Medical University

Preclinical

2 6

11c-Ps13

NNational Institute of Mental Health (NIMH)

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Long COVID1 trial

RECOVER-SLEEP: A Platform Protocol for Evaluation of Interventions for Sleep Disturbances in Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)

Completed·DDuke University·Phase 2·NCT06404112·469 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Melantonin Placebo. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Melantonin Placebo. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Duke University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: DDuke University

Melantonin Placebo

Status by Indication[2][1]

Competitive Landscape

Trials by Indication[1]

Long COVID1 trial

References

Drug Info

Quick Facts

Related News